Get started
Silence Therapeutics, Plc.Silence Therapeutics, Plc.Silence Therapeutics, Plc.

Silence Therapeutics, Plc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SLNCF chart


Full chart

SLNCF upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪295.82 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.59 USD
Net income (FY)
‪−55.08 M‬ USD
Revenue (FY)
‪32.30 M‬ USD
Shares float
‪39.01 M‬
Beta (1Y)
0.49

Employees


Employees (FY)
109
Change (1Y)
−13 −10.66%
Revenue / Employee (1Y)
‪296.35 K‬ USD
Net income / Employee (1Y)
‪−505.31 K‬ USD

About Silence Therapeutics, Plc.


Sector
Commercial Services
Industry
Miscellaneous Commercial Services
CEO
Craig Allen Tooman
Website
silence-therapeutics.com
Headquarters
London
Founded
1994
ISIN
GB00B9GTXM62
FIGI
BBG000R53MM2
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SLNCF news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SLNCF is 2.00 USD — it has decreased by −20.00% in the past 24 hours. Watch Silence Therapeutics, Plc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Silence Therapeutics, Plc. stocks are traded under the ticker SLNCF.
SLNCF stock has fallen by −41.18% compared to the previous week, the month change is a −63.64% fall, over the last year Silence Therapeutics, Plc. has showed a 146.94% increase.
We've gathered analysts' opinions on Silence Therapeutics, Plc. future price: according to them, SLNCF price has a max estimate of 24.53 USD and a min estimate of 10.14 USD. Watch SLNCF chart and read a more detailed Silence Therapeutics, Plc. stock forecast: see what analysts think of Silence Therapeutics, Plc. and suggest that you do with its stocks.
SLNCF reached its all-time high on Apr 25, 2022 with the price of 46.50 USD, and its all-time low was 0.01 USD and was reached on Jul 5, 2012. View more price dynamics on SLNCF chart.
See other stocks reaching their highest and lowest prices.
SLNCF stock is 25.00% volatile and has beta coefficient of 0.49. Track Silence Therapeutics, Plc. stock price on the chart and check out the list of the most volatile stocks — is Silence Therapeutics, Plc. there?
Yes, you can track Silence Therapeutics, Plc. financials in yearly and quarterly reports right on TradingView.
Silence Therapeutics, Plc. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
SLNCF earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.04 USD resulting in a −94.39% surprise. The estimated earnings for the next quarter are −0.04 USD per share. See more details about Silence Therapeutics, Plc. earnings.
Silence Therapeutics, Plc. revenue for the last quarter amounts to ‪1.53 M‬ USD, despite the estimated figure of ‪5.85 M‬ USD. In the next quarter, revenue is expected to reach ‪8.46 M‬ USD.
SLNCF net income for the last quarter is ‪−36.12 M‬ USD, while the quarter before that showed ‪−19.68 M‬ USD of net income which accounts for −83.59% change. Track more Silence Therapeutics, Plc. financial stats to get the full picture.
No, SLNCF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 109.00 employees. See our rating of the largest employees — is Silence Therapeutics, Plc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Silence Therapeutics, Plc. EBITDA is ‪−77.34 M‬ USD, and current EBITDA margin is −193.52%. See more stats in Silence Therapeutics, Plc. financial statements.
Like other stocks, SLNCF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Silence Therapeutics, Plc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Silence Therapeutics, Plc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Silence Therapeutics, Plc. stock shows the strong sell signal. See more of Silence Therapeutics, Plc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.